Semaglutide for BMI 27-30: Eligibility and Outcomes

Most conversations about Wegovy start with "BMI over 30." But the FDA approval has a second lane — one that matters a lot for people sitting in the overweight range who've spent years watching the obesity medication conversation pass them by.

Wegovy is also approved for adults with a BMI between 27 and 30, classified as "overweight" rather than "obese," provided they have at least one weight-related health condition. That carve-out is clinically meaningful, and a significant share of people who'd benefit most from semaglutide fall squarely in this range.

The Eligibility Rule, Explained

The full FDA-approved indication for Wegovy (semaglutide 2.4 mg) is:

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 with at least one weight-related comorbidity

The qualifying comorbidities are:

You need one of those conditions, not multiple. Someone at BMI 28 with diagnosed hypertension is fully within label. Someone at BMI 29.5 with elevated triglycerides qualifies. This is a broad list intentionally — because even modest excess weight drives real metabolic harm, and the clinical evidence supports treatment at this threshold.

Why BMI 27 Specifically?

The threshold isn't arbitrary. Evidence has consistently shown that weight-related comorbidities begin clustering meaningfully around BMI 27–28, not just at 30. Insulin resistance, elevated blood pressure, sleep apnea, and dyslipidemia all track with fat mass — particularly visceral fat — more closely than the scale implies.

Setting the bar at BMI 27 with a comorbidity targets people where pharmacological benefit is most likely to improve a health outcome, not just move the number on a scale.

The overweight-but-not-obese population is also disproportionately underserved by weight management resources. Clinicians have historically been less aggressive about treatment in this range, despite evidence that the metabolic damage is already underway. The Wegovy approval was partly a corrective to that gap.

What STEP-1 Showed for This Population

The pivotal STEP-1 trial enrolled adults with a baseline BMI of at least 30, or at least 27 with a weight-related comorbidity — mirroring the eventual FDA label. The headline result was a mean body weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg versus placebo.

The subgroup of participants starting at BMI 27–30 was smaller than the higher-BMI groups, but their outcomes tracked consistently with the overall population. Several patterns held across the full range:

• Weight loss was proportional to starting weight, not starting BMI. People in the overweight range lost a similar percentage of body weight as those with higher BMIs — the relative effect was comparable.
• Comorbidity improvements were robust. Blood pressure, lipid panels, and glycemic markers improved meaningfully — often to a degree that exceeded what the weight loss alone would predict.
• Dose-response held. Participants who reached the full 2.4 mg maintenance dose did better than those who titrated more slowly or stopped at intermediate doses.

One important caveat about STEP-1: the absolute weight loss numbers look different at lower starting BMIs. Someone at BMI 43 losing 15% drops roughly 18 kg. Someone at BMI 28 losing 15% drops around 12 kg. The relative effect is comparable; the absolute loss is smaller because there's less to lose.

The SELECT Trial: A Separate Approval Path

In 2024, Wegovy received a second FDA approval specifically for cardiovascular risk reduction — a first for an obesity medication. This was based on the SELECT trial, which enrolled adults with established cardiovascular disease and a BMI ≥ 27. The population notably did not require a diabetes diagnosis.

SELECT results: semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by approximately 20% relative to placebo over a median follow-up of around three years. The trial enrolled over 17,000 people.

For patients at BMI 27–29.9 with existing CVD, this creates a separate, standalone rationale for treatment that doesn't depend on the comorbidity eligibility path at all. Cardiovascular disease itself is the indication.

This expansion is significant. It shifts semaglutide from a weight-management drug that happens to help the heart, to a cardiovascular drug where weight reduction is a bonus.

Practical Considerations in the Overweight Range

People in the BMI 27–30 window have a somewhat different experience on semaglutide than those with higher starting BMIs. A few things to know:

Appetite suppression can feel more aggressive. Higher-BMI patients often have a larger appetite buffer — their baseline intake is higher relative to needs, so the suppression works within a larger range before hitting "eating too little." At BMI 28, the same suppression can tip into underfueling more quickly. Protein and calorie targets need active attention, particularly in the first 8–12 weeks.

Weight-loss trajectory looks different on a graph. At lower starting BMIs, weekly fluctuations take up more of the total range, so plateaus and stalls feel sharper. The underlying biology is the same; the optics are different. Tracking trends over 4–6 week windows rather than week-to-week is more informative.

Muscle preservation is proportionally more critical. A smaller total lean mass at baseline means any semaglutide-associated lean mass loss represents a higher proportion of your starting point. The same absolute muscle loss that's manageable at BMI 40 is a bigger deal at BMI 28. Protein targets and resistance training are not optional at this range — they're the difference between losing fat and losing function.

The goal line is closer. A 15% loss from BMI 28 lands at roughly BMI 23–24, which puts most people solidly in the normal range. That's a real endpoint — not just a milestone on the way to a larger number.

Coverage and Access

Insurance coverage for Wegovy at BMI 27–29.9 is less consistent than at BMI ≥ 30. Insurers often require documented prior authorization with a comorbidity listed explicitly in the chart — the same standard as the FDA label, enforced with paperwork. If your prescriber documents the qualifying condition clearly and codes the prescription appropriately, the coverage logic holds.

Practically: if you have hypertension and your prescriber writes Wegovy with hypertension as the comorbidity, the prior auth should go through. It's worth verifying before the first fill rather than after.

Compounded semaglutide is available at substantially lower cost and doesn't carry the same BMI threshold enforcement — it's prescribed off-label at the prescriber's discretion. Our compounded semaglutide guide covers what to look for in a compounding pharmacy and the current regulatory landscape for compounded versions.

Who Should Have This Conversation

If your BMI is between 27 and 30, and you have one of the qualifying comorbidities listed above, you're in the FDA-approved population. The conversation with your clinician is worth having, especially if:

• Blood pressure or lipid control is suboptimal despite consistent lifestyle effort
• You have prediabetes or impaired fasting glucose
• Weight is worsening sleep apnea or joint pain
• You have established cardiovascular disease regardless of comorbidity count

The evidence base for this population is solid. The question isn't whether semaglutide works for BMI 27–30 — the STEP data and the SELECT data make a strong case that it does. The question is whether the benefit-risk calculation makes sense for your specific situation, which is a conversation for you and your clinician.

What the Data Doesn't Tell You

A few genuinely open questions for this range:

• Optimal treatment duration. The STEP-1 trial ran 68 weeks. Long-term data beyond 2–3 years for the overweight (not obese) population is limited.
• What happens when you stop. Regain after stopping is well-documented across the BMI spectrum. The stopping semaglutide page covers what the evidence shows.
• Whether the dosing approach should differ. Some clinicians advocate for more conservative maintenance dosing in lower-BMI patients; others follow the standard titration. There's no head-to-head data here, and this is prescriber judgment territory.

The conversation about who belongs in the BMI 27–30 semaglutide population is genuinely still evolving. The comorbidity rule is clear; how aggressively to apply it is a clinical judgment, and the evidence base will continue to fill in over the next several years.

Related reading

• Semaglutide: The Complete Guide
• Dosing schedule and titration
• Preserving muscle on semaglutide
• Weight loss timeline by month